Study: Rivaroxaban is effective, but increases bleeding risk

02/8/2013 | Forbes · MedPage Today (free registration)

The anticoagulant rivaroxaban was effective at preventing venous thromboembolism in patients with acute illnesses, but it was associated with a significant increase in bleeding risk, according to a study published in the New England Journal of Medicine. The study compared rivaroxaban with enoxaparin.

View Full Article in:

Forbes · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT